New therapeutic developments in renal cell cancer

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 1, 2009, Pages 56-63

  Prenen, Hans ^a,b   Gil, Thierry ^b   Awada, Ahmad ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Angiogenesis; Molecular targeted therapy; Renal cell cancer; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CANCER VACCINE; EVEROLIMUS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FATIGUE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; THYROID DISEASE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 56449119798     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.007     Document Type: Review

References (57)

1. Patel P.H., Chaganti R.S., and Motzer R.J. Targeted therapy for metastastic renal cell carcinoma. Br J Cancer 94 (2006) 614-619
2. Martel C.L., and Lara P.N. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 45 (2003) 177-190
3. Patard J.J., Leray E., Rioux-Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23 (2005) 2763-2771
4. Board R.E., Thistlethwaite F.D., and Hawkins R.E. Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 33 (2007) 1-8
5. Javidan J., Stricker H.J., Tamboli P., et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 162 (1999) 1277-1281
6. Vogelzang N.J., Priest E.R., and Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 148 (1992) 1247-1248
7. Rosenberg S.A., Lotze M.T., Muul L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316 (1987) 889-897
8. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
9. Dilman R.O., Church D., Oldham R.K., et al. Inpatient continuous-infusion of interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group Experience. Cancer 71 (1993) 2358-2370
10. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
11. Schöffski P., Dumez H., Clement P., et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17 (2006) 1185-1196
12. Upton M.P., Parker R., Yournans A.Y., et al. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother 28 (2005) 488-495
13. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastastic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
14. Vogelzang N.J., Lipton A., and Figlin R.A. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11 (1993) 1809-1816
15. Fossa S.D., Martinelli G., Otto U., et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 3 (1992) 301-305
16. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21 (2003) 3133-3140
17. Kugler A., Stuhler G., Walden P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6 (2000) 332-336
18. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
19. Jonash E., Wood C., Tamboli P., et al. Vaccination of metastatic renal cell carcinoma patiens with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98 (2008) 1336-1341
20. Robson C.J., Churchill B.M., and Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (1969) 297-301
21. Montie J.E., Stewart B.H., Straffon R.A., Banowsky L.H., Hewitt C.B., and Montague D.K. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117 (1977) 272-275
22. Marcus S.G., Choyke P.L., Reiter R., et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150 (1993) 463-466
23. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
24. Mickisch G.H., Garin A., Van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
25. Han K.R., Pantuck A.J., Bui M.H., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61 (2003) 314-319
26. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
27. Maxwell P.H. The HIF pathway in cancer. Semin Cell Dev Biol 16 (2005) 523-530
28. Maynard M.A., and Ohh M. Molecular targets from VHL studies into the oxygen-sensing pathway. Curr Cancer Drug Targets 5 (2005) 345-356
29. Togashi A., Katagiri T., Ashida S., et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 65 (2005) 4817-4826
30. Jones J., Otu H., Spentzos D., et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11 (2005) 5730-5739
31. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
32. Raymond E., Faivre S., and Vera C. Final results of a phase I and pharmacokinetic study of SU11248, a novel multitarget tyrosine kinase inhibitor in patients with advanced cancers. Proc Am Soc Clin Oncol 22 (2003) 192
33. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
34. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
35. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
36. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
37. Srinivas S., Roigas J., Gilessen S., et al. Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 25 (2007) 5040s
38. Houk B.E., Bello C.L., Michaelson M.D., et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25 (2007) 5027s
39. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
40. Turner K.J., Moore J.W., Jones A., et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62 (2002) 2957-2961
41. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
42. Escudier B., Eisen T., and Stadler W.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
43. Tamaskar I., Bukowski R., Elson P., et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19 (2008) 265-268
44. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma. J Clin Oncol 25 (2007) 241s
45. Amato R.J., Harris P., Dalton M., et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25 (2007) 241s
46. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
47. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 370 (2007) 2103-2111
48. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO GU 2008. Abstract No 350.
49. Rugo H.S., Herbst R.S., Liu G., et al. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. J Clin Oncol 22 (2004) 2503
50. Rini B., Rixe O., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 23 (2005) 4509
51. Hutson T.E., Davis I.D., Machiels J.P., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 25 (2007) 5031
52. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
53. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
54. Motzer R.J., Mazumdar, Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
55. Dutcher J.P., Szczylik C., Tannir R., et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) (Abstract). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 243s
56. Jac J., Giessinger S., Khan M., Willis J., Chiang S., and Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) (Abstract). Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5107
57. Jac J., Amato R.J., Giessinger S., Saxena S., and Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. Proc Am Soc Clin Oncol J Clin Oncol (2008) [Abstract 5113]